Trenabull 1 - Bull Pharma

Methyltrienolone was developed in 1965 as a c-17 alpha alkylated derivative of trenbolone, designed for oral administration. It demonstrated exceptional anabolic potency in early trials but was never approved for widespread human use. Briefly explored in cancer therapy during the 1960s and early ’70s, it was soon abandoned due to its severe hepatotoxicity. Today, it remains a research compound, valued in receptor-binding studies for its resistance to metabolism and strong affinity for the androgen receptor.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Trenabull 1 by Bull Pharma, consult with your doctor or healthcare professional.